NASDAQ:NVAX - Novavax Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $186.50
  • Forecasted Upside: 259.14 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▲ +3.93 (8.19%)

This chart shows the closing price for NVAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novavax Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVAX

Analyst Price Target is $186.50
▲ +259.14% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Novavax in the last 3 months. The average price target is $186.50, with a high forecast of $209.00 and a low forecast of $150.00. The average price target represents a 259.14% upside from the last price of $51.93.

This chart shows the closing price for NVAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Novavax. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2022B. RileyLower Price Target$203.00 ➝ $181.00High
4/26/2022B. RileyLower Price TargetBuy$250.00 ➝ $203.00High
3/3/2022HC WainwrightLower Price TargetBuy$294.00 ➝ $207.00High
3/2/2022B. RileyLower Price Target$265.00 ➝ $250.00High
2/23/2022B. RileyLower Price TargetBuy$315.00 ➝ $265.00High
2/22/2022Jefferies Financial GroupInitiated CoverageBuy$198.00Medium
2/14/2022Cantor FitzgeraldLower Price TargetOverweight$282.00 ➝ $174.00High
1/21/2022CowenInitiated CoverageOutperform$150.00Medium
1/4/2022B. RileyBoost Price Target$305.00 ➝ $315.00Medium
12/21/2021JPMorgan Chase & Co.Boost Price TargetNeutral$172.00 ➝ $209.00High
9/1/2021Chardan CapitalReiterated RatingNeutralN/A
6/15/2021Cantor FitzgeraldBoost Price TargetReduce ➝ Overweight$217.00 ➝ $272.00High
5/18/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$285.00 ➝ $161.00Medium
5/12/2021B. RileyLower Price TargetBuy$365.00 ➝ $286.00High
5/12/2021Cantor FitzgeraldLower Price TargetOverweight$338.00 ➝ $217.00High
5/12/2021HC WainwrightLower Price TargetBuy$317.00 ➝ $294.00High
5/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$285.00 ➝ $161.00High
5/11/2021Jefferies Financial GroupLower Price TargetPositive ➝ Buy$310.00 ➝ $235.00Medium
3/12/2021HC WainwrightBoost Price TargetBuy$207.00 ➝ $317.00High
2/5/2021Cantor FitzgeraldBoost Price TargetOverweight$248.00 ➝ $338.00Low
2/1/2021B. RileyBoost Price TargetBuy$223.00 ➝ $334.00Low
1/29/2021Cantor FitzgeraldBoost Price TargetOverweight$211.00 ➝ $248.00High
12/14/2020Jefferies Financial GroupInitiated CoverageBuy$200.00Low
11/17/2020HC WainwrightLower Price TargetBuy$290.00 ➝ $207.00Medium
10/22/2020B. RileyLower Price Target$223.00 ➝ $257.00Low
8/17/2020B. RileyReiterated RatingBuy$257.00High
8/5/2020LADENBURG THALM/SH SHDowngradeNeutral ➝ Sell$105.00High
8/5/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$105.00 ➝ $275.00High
7/16/2020B. RileyBoost Price TargetBuy$106.00 ➝ $155.00Low
7/16/2020HC WainwrightBoost Price TargetBuy$101.00 ➝ $132.00High
7/8/2020LADENBURG THALM/SH SHReiterated RatingBuy ➝ Neutral$50.00 ➝ $105.00High
7/7/2020Cantor FitzgeraldBoost Price Target$88.00 ➝ $148.00Medium
6/29/2020B. RileyBoost Price TargetBuy$74.00 ➝ $106.00High
6/29/2020HC WainwrightBoost Price TargetBuy$50.00 ➝ $101.00High
6/19/2020Cantor FitzgeraldBoost Price TargetOverweight$45.00 ➝ $88.00High
6/5/2020B. RileyBoost Price Target$61.00 ➝ $74.00Low
6/5/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$46.00High
6/3/2020B. RileyReiterated RatingBuy$61.00Low
5/26/2020B. RileyReiterated RatingBuy$53.00 ➝ $61.00High
5/18/2020B. RileyBoost Price TargetBuy$43.00 ➝ $53.00High
5/14/2020LADENBURG THALM/SH SHBoost Price Target$38.00 ➝ $50.00Low
5/12/2020Cantor FitzgeraldBoost Price TargetOverweight$23.00 ➝ $45.00High
5/12/2020OppenheimerBoost Price TargetOutperform$19.00 ➝ $38.50High
5/12/2020B. RileyBoost Price TargetBuy$29.00 ➝ $43.00High
5/12/2020HC WainwrightReiterated RatingBuy$33.00 ➝ $50.00High
4/30/2020HC WainwrightBoost Price TargetPositive ➝ Buy$24.00 ➝ $33.00Medium
4/24/2020B. RileyBoost Price TargetBuy$20.00 ➝ $29.00Low
4/9/2020LADENBURG THALM/SH SHReiterated RatingBuy$28.00Medium
4/8/2020B. RileyReiterated RatingBuy$20.00Low
3/27/2020B. RileyBoost Price Target$15.00 ➝ $20.00High
3/25/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$16.00 ➝ $23.00High
3/25/2020HC WainwrightBoost Price TargetBuy$17.00 ➝ $24.00High
3/24/2020B. RileyBoost Price TargetBuy$15.00 ➝ $20.00High
3/24/2020LADENBURG THALM/SH SHBoost Price TargetBuy$16.00 ➝ $24.00High
3/24/2020OppenheimerBoost Price Target$13.00 ➝ $19.00Medium
3/17/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$6.00 ➝ $16.00High
2/28/2020B. RileyBoost Price TargetBuy$12.00 ➝ $16.00High
2/27/2020HC WainwrightReiterated RatingBuyHigh
1/22/2020HC WainwrightInitiated CoverageBuy$17.00High
1/21/2020B. RileyReiterated RatingBuy$12.00High
11/27/2019B. RileyInitiated CoverageBuy$12.00High
11/8/2019LADENBURG THALM/SH SHReiterated RatingBuy$27.50Low
10/17/2019Cantor FitzgeraldReiterated RatingNeutralHigh
9/24/2019B. RileySet Price TargetBuy$35.00High
9/24/2019CitigroupLower Price TargetBuy$19.00 ➝ $15.00Low
9/10/2019OppenheimerLower Price TargetOutperform$25.00 ➝ $13.00Low
8/14/2019HC WainwrightBoost Price TargetBuy ➝ Buy$10.00 ➝ $17.00High
7/1/2019HC WainwrightReiterated RatingBuy ➝ Positive$10.00 ➝ $12.00High
6/13/2019HC WainwrightSet Price TargetBuy$10.00Medium
5/13/2019OppenheimerBoost Price Target$1.25 ➝ $25.00High
5/10/2019Chardan CapitalReiterated RatingNeutral$7.00N/A
5/9/2019Cantor FitzgeraldReiterated RatingHoldHigh
5/3/2019HC WainwrightReiterated RatingBuy$40.00Low
3/19/2019Cantor FitzgeraldSet Price TargetHold$20.00High
3/19/2019HC WainwrightBoost Price TargetPositive ➝ Buy$40.00 ➝ $42.60High
3/4/2019B. RileyLower Price TargetBuy ➝ Buy$200.00 ➝ $35.00Medium
2/28/2019HC WainwrightReiterated RatingBuy$120.00High
2/28/2019JPMorgan Chase & Co.DowngradeOverweight ➝ UnderweightHigh
2/28/2019Piper Jaffray CompaniesDowngradeOverweight ➝ UnderweightHigh
1/29/2019Cantor FitzgeraldReiterated RatingHold$40.00Low
1/28/2019HC WainwrightInitiated CoverageBuy$120.00High
1/4/2019LADENBURG THALM/SH SHSet Price TargetBuy$80.00High
1/3/2019Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Positive$90.00High
12/18/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$60.00High
12/11/2018CIBCInitiated CoverageOutperform ➝ Outperform$80.00Low
12/10/2018OppenheimerInitiated CoverageOutperform$80.00 ➝ $80.00Medium
12/2/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$38.60High
11/26/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightHigh
11/23/2018Cantor FitzgeraldReiterated RatingNeutralHigh
11/19/2018Cantor FitzgeraldSet Price TargetHold$40.00Low
10/8/2018B. RileySet Price TargetBuy$200.00High
9/26/2018Cantor FitzgeraldSet Price TargetHold$40.00N/A
9/21/2018JPMorgan Chase & Co.UpgradeUnderweight ➝ Overweight$40.00 ➝ $45.00High
4/17/2018Piper Jaffray CompaniesLower Price TargetNeutral$40.00Medium
3/29/2018B. RileyReiterated RatingBuyHigh
3/19/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
3/15/2018Cantor FitzgeraldReiterated RatingHold$40.00Medium
3/1/2018Chardan CapitalReiterated RatingHoldHigh
3/1/2018CitigroupUpgradeNeutral ➝ BuyHigh
3/1/2018Piper Jaffray CompaniesBoost Price TargetNeutral$50.00High
3/1/2018LADENBURG THALM/SH SHReiterated RatingBuy$70.00High
3/1/2018B. RileySet Price TargetBuy$200.00High
2/21/2018CitigroupBoost Price TargetNeutral ➝ Neutral$40.00 ➝ $55.00Low
2/20/2018CitigroupReiterated RatingHold$60.00High
1/11/2018B. RileySet Price TargetBuy$200.00High
1/11/2018LADENBURG THALM/SH SHBoost Price TargetBuy$50.00Low
1/10/2018S&P Equity ResearchLower Price Target$36.20 ➝ $27.00High
1/5/2018B. RileySet Price TargetBuy ➝ Buy$45.00 ➝ $45.00Medium
12/19/2017CitigroupDowngradeBuy ➝ Neutral$20.00High
12/18/2017Cantor FitzgeraldReiterated RatingHold$40.00High
11/8/2017Cantor FitzgeraldReiterated RatingHold$40.00N/A
10/31/2017CitigroupUpgradeNeutral ➝ Buy$40.00N/A
8/9/2017LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$32.00High
7/27/2017Chardan CapitalReiterated RatingNeutral$30.00Low
7/26/2017Piper Jaffray CompaniesReiterated RatingHold$30.00Low
7/21/2017Cantor FitzgeraldReiterated RatingHold$40.00Low
(Data available from 5/17/2017 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 49 positive mentions
  • 16 negative mentions
  • 2 very negative mentions
  • 25 very positive mentions
  • 80 positive mentions
  • 27 negative mentions
  • 13 very negative mentions
  • 32 very positive mentions
  • 59 positive mentions
  • 15 negative mentions
  • 9 very negative mentions
  • 25 very positive mentions
  • 51 positive mentions
  • 10 negative mentions
  • 4 very negative mentions
  • 17 very positive mentions
  • 44 positive mentions
  • 8 negative mentions
  • 4 very negative mentions
  • 17 very positive mentions
  • 51 positive mentions
  • 11 negative mentions
  • 1 very negative mentions
  • 6 very positive mentions
  • 32 positive mentions
  • 9 negative mentions
  • 5 very negative mentions
  • 13 very positive mentions
  • 59 positive mentions
  • 11 negative mentions
  • 3 very negative mentions

Current Sentiment

  • 13 very positive mentions
  • 59 positive mentions
  • 11 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Novavax logo
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $51.93
Low: $47.59
High: $52.30

50 Day Range

MA: $63.40
Low: $42.92
High: $83.80

52 Week Range

Now: $51.93
Low: $41.33
High: $277.80


147,187 shs

Average Volume

6,026,150 shs

Market Capitalization

$4.06 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Novavax?

The following Wall Street analysts have issued research reports on Novavax in the last twelve months: B. Riley, Cantor Fitzgerald, Chardan Capital, Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co.,, and Zacks Investment Research.
View the latest analyst ratings for NVAX.

What is the current price target for Novavax?

6 Wall Street analysts have set twelve-month price targets for Novavax in the last year. Their average twelve-month price target is $186.50, suggesting a possible upside of 259.1%. JPMorgan Chase & Co. has the highest price target set, predicting NVAX will reach $209.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $150.00 for Novavax in the next year.
View the latest price targets for NVAX.

What is the current consensus analyst rating for Novavax?

Novavax currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVAX will outperform the market and that investors should add to their positions of Novavax.
View the latest ratings for NVAX.

How do I contact Novavax's investor relations team?

Novavax's physical mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company's listed phone number is (240) 268-2000 and its investor relations email address is [email protected] The official website for Novavax is Learn More about contacing Novavax investor relations.